Sign in

ADXS on NASDAQ

Advaxis

Logo: Advaxis, Public domain, via Wikimedia Commons5

American Pharmaceutical Company

Advaxis Immunotherapies Inc. was an American company that focused on the discovery, development, and commercialization of immunotherapies based on a genetically engineered platform based on Listeria monocytogenes (aka Lm). The company merged with Ayala Pharmaceuticals, with the newly formed company beginning operations under the name Ayala Pharmaceuticals in January 2023.3 Its shares trade on NASDAQ under the symbol ADXS.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

2002Founded1

Compare with TRAFALGAR INTERNATIONAL, INC., PRF Technologies Ltd. or BIOADAPTIVES, INC., or pick any stock.

  • TickerADXS on NASDAQ1
  • Industrybiotechnology1
  • HeadquartersPrinceton1
  • Websitewww.advaxis.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address9 Deer Park Drive, Suite K-1, Monmouth Junction, Nj 088526
  • Filer categoryNon-accelerated filer, Smaller reporting company6
  • LEI549300W71T0G7C14IM074
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O National Registered Agents, Inc., 19904 Dover, United States4
  • Registered withDivision of Corporations, Department of State, 34972924

See how the biggest companies compare on our leaderboards

Advaxis Immunotherapies Inc. was an American company that focused on the discovery, development, and commercialization of immunotherapies based on a genetically engineered platform based on Listeria monocytogenes (aka Lm). The company merged with Ayala Pharmaceuticals, with the newly formed company beginning operations under the name Ayala Pharmaceuticals in January 2023.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-278969.2%Operating margin8
-369784.6%Net margin8
-98.1%Revenue growth, 20238

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue0¢$13.0K
  • Research and development86¢$24.1M
  • Income tax14¢$3.9M

Out of $13.0K in revenue.8 The company lost money this year.

Financial statements

Revenue9101112138$13.0K in 2023−100% since 2017
0$10.0M$20.0M$30.0M2017: $12.0M$12.0M20172018: $6.1M$6.1M2018−50%2019: $20.9M$20.9M2019+244%2020: $253.0K$253.0K2020−99%2021: $3.2M$3.2M2021+1181%2022: $692.0K$692.0K2022−79%2023: $13.0K$13.0K2023−98%
Operating income9101112138-$36.3M in 2023−63% since 2017
-$100.0M-$75.0M-$50.0M-$25.0M02017: -$98.4M-$98.4M20172018: -$70.4M-$70.4M2018−29%2019: -$18.0M-$18.0M2019−74%2020: -$26.4M-$26.4M2020+47%2021: -$18.8M-$18.8M2021−29%2022: -$37.5M-$37.5M2022+100%2023: -$36.3M-$36.3M2023−3%
Net income9101112138-$48.1M in 2023−49% since 2017
-$100.0M-$75.0M-$50.0M-$25.0M02017: -$93.4M-$93.4M20172018: -$66.5M-$66.5M2018−29%2019: -$16.6M-$16.6M2019−75%2020: -$26.5M-$26.5M2020+59%2021: -$17.9M-$17.9M2021−33%2022: -$38.0M-$38.0M2022+113%2023: -$48.1M-$48.1M2023+26%
Fiscal year2017201820192020202120222023
Revenue$12.0M9$6.1M10$20.9M11$253.0K12$3.2M13$692.0K8$13.0K8
Cost of revenue$602.0K8$13.0K8
Gross profit$90.0K8
Research and development$70.5M9$57.0M10$26.7M11$15.6M12$10.6M13$27.9M8$24.1M8
Operating expenses$22.0M13$19.6M13
Operating income-$98.4M9-$70.4M10-$18.0M11-$26.4M12-$18.8M13-$37.5M8-$36.3M8
Interest
Income before tax-$17.8M13-$37.4M8-$52.0M8
Income tax-$4.4M9$50.0K10$50.0K11$50.0K12$50.0K13$584.0K8-$3.9M8
Net income-$93.4M9-$66.5M10-$16.6M11-$26.5M12-$17.9M13-$38.0M8-$48.1M8
Earnings per share-$11.0713-$13.138-$7.998
Earnings per share (diluted)-$13.138-$7.998
Shares (weighted, basic)1.6M shares132.9M shares86.0M shares8
Shares (weighted, diluted)2.9M shares86.0M shares8

Compare Advaxis with another company

Corporate structure

Advaxis sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Advaxis

  • Advaxis Princeton, New Jersey, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.

What it owns

What Advaxis reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$94.0K13 Oct 31, 2022$179.0K13 Oct 31, 2021−47.5%
Computer equipment and software$24.0K13 Oct 31, 2022$241.0K13 Oct 31, 2021−90.0%
Property and equipment, before depreciation$1.4M8 Dec 31, 2023$1.6M8 Dec 31, 2022−16.5%
Accumulated depreciation$812.0K8 Dec 31, 2023$660.0K8 Dec 31, 2022+23.0%
Property and equipment, net$540.0K8 Dec 31, 2023$960.0K8 Dec 31, 2022−43.8%
Operating-lease assets (leased space)$102.0K8 Dec 31, 2023$1.5M8 Dec 31, 2022−93.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.9M8 Dec 31, 2023$2.4M8 Dec 31, 2022+102.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$4.5M8 Dec 31, 2023
Intangible assets, net (excluding goodwill)$3.9M8 Dec 31, 2023$110.0K13 Oct 31, 2022+3443.6%
Finite-lived intangibles, gross$3.8M8 Dec 31, 2023$110.0K13 Oct 31, 2022+3354.5%
Finite-lived intangibles, net$3.9M8 Dec 31, 2023$110.0K13 Oct 31, 2022+3443.6%
Patents, net$95.0K13 Oct 31, 2022$4.8M13 Oct 31, 2021−98.0%
Licenses, net$15.0K13 Oct 31, 2022$777.0K13 Oct 31, 2021−98.1%

The story

Beginnings

Advaxis was a Delaware corporation when it was acquired by a shell corporation in November 2004. The acquiring company was Great Expectations, which was incorporated in Colorado in June 1987. The only operating company owned by Great Expectations was Advaxis. In December 2004, a month after the acquisition, Great Expectations changed its name to Advaxis, and 18 months later it reincorporated as a Delaware corporation. The company's official 'date of inception' is 1 March 2002.

Partnerships

In 2014, Advaxis entered a co-development and commercialization agreement with India's Biocon for the ADXS-HPV therapeutic in the Indian market, addressing HPV-associated cancers, including cervical cancer.,

From Wikipedia’s article on Advaxis, shared under CC BY-SA 4.0.7

Leadership

Who has led Advaxis, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Kenneth A. Berlin2018–2020

President

  1. Kenneth A. Berlin2018–2020

Chief financial officer

  1. Mark J. Rosenblum2010–2014
  2. Sara Bonstein2014–2018
  3. Molly Henderson2018–2020
  4. Roy Golan2023

Chief operating officer

  1. Gregory T. Mayes2013–2016
20052010201520202025
Board members and other officers (23)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • EVP and Chief Medical OfficerAndres A. Gutierrez named Feb 11, 2022 to Nov 2, 202346
  • DirectorRichard Berman named Feb 11, 202247

Products and brands

Advaxis immunotherapies are based on a platform technology using live attenuated Listeria monocytogenes (Lm) that are bioengineered to secrete an antigen/adjuvant fusion protein. The vectors infect the key elements of the immune system, and the secreted antigen/adjuvant fusion protein redirects the immune response against the cancer itself. The adjuvant also reduces the cancer's defense against this immune attack. The company's platform technology is based on preclinical research by Yvonne Paterson, Professor of Microbiology at the University of Pennsylvania, and Fellow of the American Academy for the Advancement of Science.

From Wikipedia’s article on Advaxis, shared under CC BY-SA 4.0.7

Former names

  • Advaxis, Inc.Jan 6, 2005 to Jan 13, 20236
  • GREAT EXPECTATIONS & ASSOCIATES INCDec 14, 1999 to Jan 5, 20056

Timeline

  1. Apr 19, 20248-K Financial statements and exhibits48
  2. Apr 3, 20248-K Executive or director change49
  3. Mar 29, 20248-K Completed an acquisition or sale; Unregistered sale of shares; Regulation FD disclosure50
  4. Mar 5, 20248-K Entered a material agreement; New debt or obligation51
  5. Feb 23, 20248-K Executive or director change52
  6. Feb 9, 20248-K Unregistered sale of shares; Shareholder vote53
  7. Feb 6, 20248-K Entered a material agreement; Executive or director change; Regulation FD disclosure54
  8. Jan 3, 20248-K Financial statements and exhibits55
  9. Oct 20, 20238-K Completed an acquisition or sale; Unregistered sale of shares; Executive or director change56
  10. Sep 21, 20238-K Entered a material agreement; Unregistered sale of shares57
  11. Aug 1, 20238-K Entered a material agreement; Shareholder vote; Other events58
  12. Apr 7, 20238-K Change of auditor59
  13. Apr 25, 2018New chief executive Kenneth A. Berlin becomes CEO18
  14. 2002Founded Founded1

Filings

144 filings to the SEC since October 2021: 4 annual reports, 6 quarterly reports, 38 major events, 21 insider forms, 10 large holders, 2 private raises, 63 other. The latest 20:

  1. May 9, 202415-12G EDGAR
  2. Apr 26, 202410-K/A EDGAR
  3. Apr 19, 20248-K/A EDGAR
  4. Apr 16, 202410-K EDGAR
  5. Apr 15, 2024S-8 POS EDGAR
  6. Apr 15, 2024S-8 POS EDGAR
  7. Apr 15, 2024S-8 POS EDGAR
  8. Apr 15, 2024S-8 POS EDGAR
  9. Apr 15, 2024S-8 POS EDGAR
  10. Apr 15, 2024S-8 POS EDGAR
  11. Apr 15, 2024S-8 POS EDGAR
  12. Apr 15, 2024S-8 POS EDGAR
  13. Apr 15, 2024S-8 POS EDGAR
  14. Apr 3, 20248-K EDGAR
  15. Apr 1, 2024NT 10-K NOTIFICATION OF LATE FILING EDGAR
  16. Mar 29, 20248-K EDGAR
  17. Mar 6, 20244 EDGAR
  18. Mar 5, 2024DEFM14C EDGAR
  19. Mar 5, 20248-K EDGAR
  20. Feb 23, 20248-K EDGAR

The 144 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 18, 2023Israel Biotech Fund GP Partners II, L.P.DirectorBuy1,317,716Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Stakes it holds

Advaxis has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$5.2M 2022–2023
Money received by yearMoney received by year, 2022–2023: $5.2M in all. Private raises (Form D) $5.2M.$0$2M$4M$6M2022 · Private raises (Form D): $4.8M20222023 · Private raises (Form D): $433.8K2023
Figures by year
YearPrivate raises (Form D)Total
2023$433.8K$433.8K
2022$4.8M$4.8M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Oct 18, 2023Raised $433,825 in a private offering of equity46 Form D: 3 investors so far Form D
  2. Jan 31, 2022Raised $4.8 million in a private offering of equity47 Form D: 6 investors so far Form D

SEC filer profile

How Advaxis is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAyala Pharmaceuticals, Inc.2
  • CIK0001100397
  • Employer ID (EIN)84-15219552
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ 088522
  • Phone732 545 15902
  • Shares outstanding42,633,400 as of Apr 8, 202465
  • Public float$3.7M as of Jun 30, 202365
  • On EDGAR sinceDec 14, 19992
  • Filings1,330 in all: 4 (424), 8-K (271), 424B3 (59), 10-Q (45), 3 (36), SC 13G/A (36), DEFA14A (30), 10QSB (27)2
    All 66 form types

    EFFECT (27), SC 13G (24), 424B5 (21), CORRESP (20), UPLOAD (18), DEF 14A (17), SB-2/A (16), 10-K (15), D (14), S-1 (14), S-1/A (13), 8-K/A (12), POS AM (12), 425 (11), NT 10-Q (11), PRE 14A (10), 10-K/A (9), 10KSB (9), 3/A (9), 4/A (9), S-8 (9), S-8 POS (9), 10QSB/A (8), CT ORDER (8), 10-Q/A (6), 10KSB/A (6), NT 10-K (6), SC 13D (6), SC 13D/A (5), S-3 (4), SB-2 (4), 424B4 (3), DEFR14A (3), S-4/A (3), 25-NSE (2), 8-A12B (2), NTN 10K (2), REGDEX (2), RW (2), S-3/A (2), S-4 (2), 10SB12G (1), 15-12G (1), 424B2 (1), ARS (1), AW (1), CERTNAS (1), DEF 14C (1), DEFM14A (1), DEFM14C (1), FWP (1), PRE 14C (1), PREM14C (1), PX14A6G (1), S-1MEF (1), S-3MEF (1), SC 14F1 (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Apr 16, 2024
    Quarterly report (10-Q) Nov 20, 2023
    Proxy statement (DEF 14A) Jun 23, 2023
    Latest 8-K (8-K) Apr 3, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65